Skip to main navigation
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact

News

Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH
NeurologyLive
April 25, 2023
Novel MS Drug Good as Gold in Phase II Study
Medpagetoday
April 25, 2023
ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein
Biopharma Dive
March 27, 2023
CNM-Au8 found to delay clinical worsening in ALS HEALEY trial
ALS News Today
March 10, 2023
ALS Advances and Hot Topics for MDA 2023: Matthew B. Harms, MD
NeurologyLive
March 9, 2023
CNM-Au8 Demonstrates Significant Survival Benefit in HEALEY-ALS Interim Analysis
NeurologyLive
March 9, 2023
Clene's Nanocrystal ALS treatment bounces back with positive data
BioSpace
March 9, 2023
MS New Notes: Briumvi, vitamin D, CNM-Au8
Multiple Sclerosis News Today
March 6, 2023
ACTRIMS 2023 – Michael Hotchkin, Chief Development Officer, Clene Inc.
Multiple Sclerosis News Today
February 27, 2023
CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter
NeurologyLive
February 14, 2023

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »


1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved